Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis

JAMA

Volumn 311, Issue 18, 2014, Pages 1889-1900

  Jonas, Daniel E ^a,b   Amick, Halle R ^b   Feltner, Cynthia ^a,b   Bobashev, Georgiy ^c   Thomas, Kathleen ^b   Wines, Roberta ^b   Kim, Mimi M ^b,d   Shanahan, Ellen ^b   Gass, C Elizabeth ^a   Rowe, Cassandra J ^e   Garbutt, James C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c RTI INTERNATIONAL   (United States)

^d DUKE UNIVERSITY   (United States)

^e University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; NALMEFENE; NALTREXONE; PLACEBO; TOPIRAMATE;

ALCOHOL CONSUMPTION; ALCOHOL USE DISORDER; ALCOHOLISM; ANXIETY DISORDER; COGNITIVE DEFECT; COHORT ANALYSIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; INJURY; INSOMNIA; META ANALYSIS; MORTALITY; NAUSEA; OFF LABEL DRUG USE; OUTPATIENT CARE; PARESTHESIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TASTE DISORDER; TRAFFIC ACCIDENT; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ALCOHOL-RELATED DISORDERS; FRUCTOSE; HARM REDUCTION; HUMANS; NALTREXONE; OUTPATIENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAURINE;

EID: 84900333411     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.3628     Document Type: Review

References (108)

1. Mann K, Schäfer DR, Längle G, Ackermann K, Croissant B. The long-term course of alcoholism, 5, 10 and 16 years after treatment. Addiction. 2005;100(6):797-805. (Pubitemid 40769824)
2. Norström T. Per capita alcohol consumption and all-cause mortality in Canada, 1950-98. Addiction. 2004;99(10):1274-1278. (Pubitemid 39330931)
3. Rivara FP, Garrison MM, Ebel B, McCarty CA, Christakis DA. Mortality attributable to harmful drinking in the United States, 2000. J Stud Alcohol. 2004;65(4):530-536. (Pubitemid 39100928)
4. National Collaborating Centre for Mental Health. Alcohol-Use Disorders: Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence: National Clinical Practice Guideline 115. London, England: National Institute for Health & Clinical Excellence; 2011.
5. Schuckit MA. Alcohol-use disorders. Lancet. 2009;373(9662):492-501.
6. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2007;64(7):830-842. (Pubitemid 47026379)
7. Mertens JR, Weisner C, Ray GT, Fireman B, Walsh K. Hazardous drinkers and drug users in HMO primary care: prevalence, medical conditions, and costs. Alcohol Clin Exp Res. 2005;29(6):989-998. (Pubitemid 40934203)
8. Teesson M, Baillie A, Lynskey M, Manor B, Degenhardt L. Substance use, dependence and treatment seeking in the United States and Australia: a cross-national comparison. Drug Alcohol Depend. 2006;81(2):149-155. (Pubitemid 41821798)
9. Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for Adults With Alcohol-Use Disorders in Outpatient Settings. Comparative Effectiveness Review No. 134. (Prepared by the RTI International-University of North Carolina Evidence-based Practice Center under Contract 290-2012-00008-I.) AHRQ publication 14-EHC029-EF. Rockville, MD: Agency for Healthcare Research and Quality; May 2014.
10. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Agency for Healthcare Research and Quality. http://effectivehealthcare.ahrq.gov/ ehc/products/60/318/CER-Methods-Guide-140109.pdf. Accessed April 21, 2014.
11. Viswanathan M, Ansari MT, Berkman ND, et al. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. Rockville, MD: Agency for Healthcare Research and Quality Methods Guide for Comparative Effectiveness Reviews. AHRQ publication 12-EHC047-EF. http://www.ncbi.nlm.nih.gov/books/NBK91433/pdf/cerguidebias.pdf. Accessed April 21, 2014.
12. Sutton AJ, Abrams KR, Jones DR, et al. Methods for Meta-Analysis in Medical Research [Wiley Series in Probability and Statistics: Applied Probability and Statistics Section]. London, England: Wiley; 2000.
13. Higgins JP, Thompson SG. Quantifying heterogeneity in ameta-analysis. Stat Med. 2002;21(11):1539-1558.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency inmeta-analyses. BMJ. 2003;327(7414):557-560.
15. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ. 2007;176(8):1091-1096. (Pubitemid 46649731)
16. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]: 10.4.1: Funnel plots. http://handbook.cochrane.org/chapter-10/10-4-1-funnel-plots.htm. Accessed April 16, 2014.
17. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-1101.
18. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions: Agency for Healthcare Research and Quality and the effective health-care program. J Clin Epidemiol. 2010;63(5):513-523.
19. Barrias JA, Chabac S, Ferreira L, Fonte A, Potgieter A, Teixeira de Sousa E. Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study [in Portuguese]. Psiquiatria Clinica. 1997;18:149-160.
20. Huang X, Huang X, Peng H, Mai G. Placebo-controlled trial of naltrexone in outpatient treatment of alcohol dependence [in Chinese]. Chin Ment Health J. 2002;16(5):302-303.
21. Krupitski EM, Burakov AM, Ivanov VB, et al. The use of baclofen for treating affective disorders in alcoholism [in Russian]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova /Ministerstvo zdravookhraneniia i meditsinsko. 1994;94(1):57-61.
22. Ladewig D, Knecht T, Leher P, Fendl A. Acamprosate: a stabilizing factor in long-term withdrawal of alcoholic patients [in German]. Ther Umsch. 1993;50(3):182-188. (Pubitemid 23135166)
23. Castro LA, Laranjeira R. A double blind, randomized and placebo-controlled clinical trial with naltrexone and brief intervention in outpatient treatment of alcohol dependence [in Portuguese]. J Bras Psiquiatr. 2009;58(2):79-85.
24. Roussaux JP, Hers D, Ferauge M. Does acamprosate diminish the appetite for alcohol in weaned alcoholics? [in French]. J Pharm Belg. 1996;51(2):65-68. (Pubitemid 26155326)
25. Geerlings P, Ansoms C, Van DBW. Acamprosate and relapse prevention in outpatient alcoholics: results from a randomized, placebo-controlled double-blind study in the Benelux. Tijdschrift Voor Alcohol Drugs En Andere Psychotrope Stoffen. 1995;21(3):129-141. (Pubitemid 26367786)
26. Kiefer F, Jahn H, Holzbach R, et al. The NALCAM study: efficacy, tolerability, outcome. Sucht. 2003;49(6):342-351.
27. Sass H, Mann K, Soyka M. Drug support for prevention of relapse in alcoholic patients with acamprosate: results of a double blind, randomized, placebo controlled study. Sucht. 1996;42(5):316-322. (Pubitemid 26378721)
28. Sass H, Soyka M, Mann K, Zieglgänsberger W. Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 1996;53(8):673-680. (Pubitemid 26269327)
29. Narayama PL, Gupta AK, Sharma PK. Use of anti-craving agents in soldiers with alcohol dependence syndrome. Med J Armed Forces India. 2008;64(4):320-324.
30. Anton RF, O'Malley SS, Ciraulo DA, et al COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003-2017. (Pubitemid 44794003)
31. Fuller RK, Roth HP. Disulfiramfor the treatment of alcoholism: an evaluation in 128 men. Ann Intern Med. 1979;90(6):901-904. (Pubitemid 9229637)
32. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiramtreatment of alcoholism: a Veterans Administration cooperative study. JAMA. 1986;256(11):1449-1455. (Pubitemid 16014332)
33. LoCastro JS, Youngblood M, Cisler RA, et al. Alcohol treatment effects on secondary nondrinking outcomes and quality of life: the COMBINE study. J Stud Alcohol Drugs. 2009;70(2):186-196.
34. Morgenstern J, Kuerbis AN, Chen AC, Kahler CW, Bux DA Jr, Kranzler HR. A randomized clinical trial of naltrexone and behavioral therapy for problem drinking men who have sex with men. J Consult Clin Psychol. 2012;80(5):863-875.
35. Pettinati HM, Gastfriend DR, Dong Q, Kranzler HR, O'Malley SS. Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. Alcohol Clin Exp Res. 2009;33(2):350-356.
36. O'Malley SS, Robin RW, Levenson AL, et al. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. Alcohol Clin Exp Res. 2008;32(7):1271-1283.
37. Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res. 2006;40(5):383-393. (Pubitemid 43816589)
38. Morley KC, Teesson M, Reid SC, et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction. 2006;101(10):1451-1462. (Pubitemid 44337770)
39. Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;60(1):92-99. (Pubitemid 36070869)
40. Mann K, Lemenager T, Hoffmann S, et al PREDICT Study Team. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol. 2013;18(6):937-946.
41. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999;56(8):719-724. (Pubitemid 29357733)
42. Brady KT, Myrick H, Henderson S, Coffey SF. The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend. 2002;67(3):323-330. (Pubitemid 34786267)
43. Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2005;62(1):37-45. (Pubitemid 40096069)
44. Garbutt JC, Kranzler HR, O'Malley SS, et al Vivitrex Study Group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617-1625. (Pubitemid 40471792)
45. Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol. 2001;36(5):413-418. (Pubitemid 32851423)
46. Berger L, Fisher M, Brondino M, et al. Efficacy of acamprosate for alcohol dependence in a family medicine setting in the United States: a randomized, double-blind, placebo-controlled study. Alcohol Clin Exp Res. 2013;37(4):668-674.
47. Baltieri DA, De Andrade AG. Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting. J Stud Alcohol. 2004;65(1):136-139. (Pubitemid 38200627)
48. Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiramin the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res. 1998;22(3):573-579. (Pubitemid 28242460)
49. Chick J, Howlett H, Morgan MY, Ritson B. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol. 2000;35(2):176-187. (Pubitemid 30248621)
50. Chick J, Anton R, Checinski K, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000;35(6):587-593.
51. Geerlings PJ, Ansoms C, Van Den Brink W. Acamprosate and prevention of relapse in alcoholics. Results of a randomized, placebo-controlled, double-blind study in out-patient alcoholics in the Netherlands, Belgium and Luxembourg. Eur Addict Res. 1997;3(3):129-137. (Pubitemid 27296632)
52. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995;30(2):239-247.
53. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: a 90-day placebo-controlled dose-finding study. Br J Psychiatry. 1997;171:73-77.
54. Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction. 1997;92(11):1537-1546. (Pubitemid 27499564)
55. Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol. 2000;35(2):202-209. (Pubitemid 30248625)
56. Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet. 1996;347(9013):1438-1442. (Pubitemid 26161206)
57. Oslin DW, Lynch KG, Pettinati HM, et al. A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. Alcohol Clin Exp Res. 2008;32(7):1299-1308.
58. Pettinati HM, Oslin DW, Kampman KM, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry. 2010;167(6):668-675.
59. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999;156(11):1758-1764. (Pubitemid 29517569)
60. Balldin J, Berglund M, Borg S, et al. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res. 2003;27(7):1142-1149. (Pubitemid 36890391)
61. Gastpar M, Bonnet U, Böning J, et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol. 2002;22(6):592-598. (Pubitemid 35416785)
62. Guardia J, Caso C, Arias F, et al. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res. 2002;26(9):1381-1387.
63. Killeen TK, Brady KT, Gold PB, et al. Effectiveness of naltrexone in a community treatment program. Alcohol Clin Exp Res. 2004;28(11):1710-1717. (Pubitemid 39551832)
64. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA; Veterans Affairs Naltrexone Cooperative Study 425 Group. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;345(24):1734-1739.
65. Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction. 2001;96(11):1565-1573.
66. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49(11):881-887.
67. O'Malley SS, Sinha R, Grilo CM, et al. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial. Alcohol Clin Exp Res. 2007;31(4):625-634. (Pubitemid 46434899)
68. Oslin D, Liberto JG, O'Brien J, Krois S, Norbeck J. Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry. 1997;5(4):324-332. (Pubitemid 27483912)
69. Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Rounsaville B; VA New England VISN IMIRECC Study Group. Naltrexone and disulfiramin patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry. 2005;57(10):1128-1137. (Pubitemid 40615774)
70. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry. 1997;54(8):737-742. (Pubitemid 27344101)
71. Kranzler HR, Wesson DR, Billot L; DrugAbuse Sciences Naltrexone Depot Study Group. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res. 2004;28(7):1051-1059. (Pubitemid 38955203)
72. Anton RF, Moak DH, Latham P, et al. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol. 2005;25(4):349-357. (Pubitemid 41060255)
73. Wölwer W, Frommann N, Jänner M, et al. The effects of combined acamprosate and integrative behaviour therapy in the outpatient treatment of alcohol dependence: a randomized controlled trial. Drug Alcohol Depend. 2011;118(2-3):417-422.
74. Latt NC, Jurd S, Houseman J, Wutzke SE. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust. 2002;176(11):530-534. (Pubitemid 34649401)
75. Monti PM, Rohsenow DJ, Swift RM, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res. 2001;25(11):1634-1647. (Pubitemid 33104926)
76. ALK21-014: Efficacy and safety of Medisorb naltrexone (Vivitrol) after enforced abstinence; 2011. http://www.clinicaltrials.gov/ct2/show/NCT00501631. Accessed April 22, 2014.
77. Johnson BA, Rosenthal N, Capece JA, et al Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641-1651. (Pubitemid 47606653)
78. Kampman KM, Pettinati HM, Lynch KG, Spratt K, Wierzbicki MR, O'Brien CP. A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend. 2013;133(1):94-99.
79. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361(9370):1677-1685. (Pubitemid 36577440)
80. Gual A, He Y, Torup L, van den Brink W, Mann K; ESENSE 2 Study Group. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. 2013;23(11):1432-1442.
81. Mann K, Bladström A, Torup L, Gual A, van den Brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry. 2013;73(8):706-713.
82. Anton RF, Pettinati H, Zweben A, et al. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol. 2004;24(4):421-428. (Pubitemid 38944141)
83. Karhuvaara S, Simojoki K, Virta A, et al. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol Clin Exp Res. 2007;31(7):1179-1187. (Pubitemid 46934385)
84. Revia (naltrexone hydrochloride) [package insert]. Pomona, NY: Duramed Pharmaceuticals; 2009.
85. Corrao G, Bagnardi V, Zambon A, La Vecchia C. Ameta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med. 2004;38(5):613-619. (Pubitemid 38452887)
86. Jonas DE, Garbutt JC, Amick HR, et al. Behavioral counseling after screening for alcohol misuse in primary care: a systematic review and meta-analysis for the US Preventive Services Task Force. Ann Intern Med. 2012;157(9):645-654.
87. Rehm J, Baliunas D, Borges GL, et al. The relation between different dimensions of alcohol consumption and burden of disease: an overview. Addiction. 2010;105(5):817-843.
88. Bondy SJ, Rehm J, Ashley MJ, Walsh G, Single E, Room R. Low-risk drinking guidelines: the scientific evidence. Can J Public Health. 1999;90(4):264-270. (Pubitemid 29403235)
89. Shalala DE. 10th Special Report to the US Congress on Alcohol and Health: Highlights From Current Research: From the Secretary of Health and Human Services. http://pubs.niaaa.nih.gov/publications/10report/intro.pdf. Accessed April 21, 2014.
90. Centers for Disease Control and Prevention (CDC). Alcohol-attributable deaths and years of potential life lost: United States, 2001. MMWR Morb Mortal Wkly Rep. 2004;53(37):866-870.
91. Cherpitel CJ, Ye Y. Alcohol-attributable fraction for injury in the US general population: data from the 2005 National Alcohol Survey. J Stud Alcohol Drugs. 2008;69(4):535-538.
92. Rehm J, Shield KD, Gmel G, Rehm MX, Frick U. Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. Eur Neuropsychopharmacol. 2013;23(2):89-97.
93. Zarkin GA, Bray JW, Aldridge A, et al. The effect of alcohol treatment on social costs of alcohol dependence: results from the COMBINE study. Med Care. 2010;48(5):396-401.
94. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
95. Hasin DS, O'Brien CP, Auriacombe M, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry. 2013;170(8):834-851.
96. Kranzler HR, Armeli S, Tennen H, et al. Targeted naltrexone for early problem drinkers. J Clin Psychopharmacol. 2003;23(3):294-304. (Pubitemid 36813992)
97. Moyer VA; Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(3):210-218.
98. Jonas DE, Garbutt JC, Brown JM, et al. Screening, Behavioral Counseling, and Referral in Primary Care to Reduce Alcohol Misuse: Comparative Effectiveness Review No. 64: AHRQ publication 12-EHC055-EF. http://effectivehealthcare.ahrq. gov/index.cfm/search-for-guides-reviews-and-reports/?productid= 1135&pageaction=displayproduct. Accessed April 16, 2014.
99. O'Connor PG. Managing substance dependence as a chronic disease: is the glass half full or half empty? JAMA. 2013;310(11):1132-1134.
100. Harris AH, Kivlahan DR, Bowe T, Humphreys KN. Pharmacotherapy of alcohol use disorders in the Veterans Health Administration. Psychiatr Serv. 2010;61(4):392-398.
101. Harris AH, Oliva E, Bowe T, Humphreys KN, Kivlahan DR, Trafton JA. Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence. Psychiatr Serv. 2012;63(7):679-685.
102. Pettinati HM, Weiss RD, Miller WR, Donovan D, Ernst DB, Rounsaville BJ. Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence: COMBINE Monograph Series. Vol 2. DHHS publication (NIH) 04-5289. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2004.
103. Kiritzé-Topor P, Huas D, Rosenzweig C, Comte S, Paille F, Lehert P. A pragmatic trial of acamprosate in the treatment of alcohol dependence in primary care. Alcohol Alcohol. 2004;39(6):520-527. (Pubitemid 39534535)
104. O'Malley SS, Rounsaville BJ, Farren C, et al. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials. Arch Intern Med. 2003;163(14):1695-1704. (Pubitemid 36898958)
105. Oslin DW, Lynch KG, Maisto SA, et al. A randomized clinical trial of alcohol care management delivered in Department of Veterans Affairs primary care clinics versus specialty addiction treatment. J Gen Intern Med. 2014;29(1):162-168.
106. Saitz R, Cheng DM, Winter M, et al. Chronic care management for dependence on alcohol and other drugs: the AHEAD randomized trial. JAMA. 2013;310(11):1156-1167.
107. Kissin B, Charnoff SM, Rosenblatt SM. Drug and placebo responses in chronic alcoholics. Psychiatr Res Rep AmPsychiatr Assoc. 1968;24:44-60.
108. Polich JM, Armor DJ, Braiker HB. Stability and Change in Drinking Patterns: The Course of Alcoholism: Four Years After Treatment. New York, NY: John Wiley & Sons; 1981:159-200.